Skip to main content

Advertisement

SpringerLink
Log in

Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis

Recommendations for use of abatacept in patients with rheumatoid arthritis

  • Empfehlungen und Stellungnahmen von Fachgesellschaften
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Alten R, Märker-Hermann E (2010) Selektive Kostimulationsblockade. CTLA4-Ig (Abatacept). Z Rheumatol 69:601–607

    Article  CAS  PubMed  Google Scholar 

  2. Furst DE, Keystone EC, So AK et al (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 72(Suppl III) ii2–ii34

  3. Kremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865–876

    Article  CAS  PubMed  Google Scholar 

  4. Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123

    Article  CAS  PubMed  Google Scholar 

  5. Krüger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012. Z Rheumatol 71:592–603

    Article  PubMed  Google Scholar 

  6. Manger B, Michels H, Nüsslein H et al (2007) Neufassung der Empfehlungen der DGRh zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen (Stand März 2006). Z Rheumatol 66:72–75

    Article  CAS  PubMed  Google Scholar 

  7. Kim PS, Ho GY, Prete PE, Furst DE (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res 64:1265–1268

    CAS  Google Scholar 

  8. Fachinformation ORENCIA®, 2013

  9. Moreland LW, Alten R, Bosch F van den et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470–1479

    Article  CAS  PubMed  Google Scholar 

  10. Schiff MH, Pritchard C, Huffstutter JE et al (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE-trial. Ann Rheum Dis 68:1708–1714

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Tay L, Leon F, Vratsanos G et al (2007) Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 9:R38

    Article  PubMed Central  PubMed  Google Scholar 

  12. Ribeiro AC, Laurindo IM, Guedes LK et al (2013) Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res 65:476–480

    Article  CAS  Google Scholar 

  13. Nishida K, Nasu Y, Hashizume K et al (2014) Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol doi:10.3109/14397595.2013.874758

    Google Scholar 

  14. Krüger K, Albrecht K, Rehart S et al (2014) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen Vorgehensweise unter Therapie mit DMARDs und Biologika bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 73:77–84

    Article  PubMed  Google Scholar 

  15. Genant HK, Peterfy CG, Westhovens R et al (2008) Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the longterm extension of the AIM trial. Ann Rheum Dis 67:1084–1089

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Kremer JM, Russell AS, Emery P et al (2011) Long-term safety, efficacy, and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 70:1826–1830

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Genovese MC, Schiff M, Luggen M et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547–554

    Article  CAS  PubMed  Google Scholar 

  18. Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Weinblatt ME, Schiff M, Valente R et al (2013) Head-to-head comparison of subcutaneous abatacept vs adalimumab for rheumatoid arthritis. Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65:28–38

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Schiff M, Weinblatt ME, Valente R et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86–94

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Emery P, Durez P, Dougados M et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Westhovens R, Robles M, Ximenes AC et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Wells AF, Westhovens R, Reed DM et al (2011) Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol 38:2362–2368

    Article  CAS  PubMed  Google Scholar 

  24. Genovese MC, Covarrubias A, Leon G et al (2011) Subcutaneous abatacept versus intravenous abatacept. A pahse III noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63:2854–2864

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Keystone EC, Kremer JM, Russell A et al (2012) Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 71:857–861

    Article  CAS  PubMed  Google Scholar 

  26. Kremer JM, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept. Arthritis Rheum 52:2263–2271

    Article  CAS  PubMed  Google Scholar 

  27. Genovese MC, Schiff M, Luggen M et al (2012) Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 39:1546–1554

    Article  CAS  PubMed  Google Scholar 

  28. Weinblatt ME, Moreland LW, Westhovens R et al (2013) Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years treatment from the abatacept clinical trial program. J Rheumatol 40:787–797

    Article  CAS  PubMed  Google Scholar 

  29. Weinblatt M, Combe B, Covucci A et al (2006) safety of the selective co-stimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non-biologic DMARDs: a 1 year randomised study. Arthritis Rheum 54:2807–2816

    Article  CAS  PubMed  Google Scholar 

  30. Weinblatt M, Schiff M, Goldman A et al (2007) Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66:228–234

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 68:25–32

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Curtis JR, Xie F, Chen L et al (2011) The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70:1401–1406

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Simon TA, Askling J, Lacaille D et al (2010) Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther 12:R67

    Article  PubMed Central  PubMed  Google Scholar 

  34. Simon TA, Smitten AL, Franklin J et al (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68:1819–1826

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Haggerty HG, Abbott MA, Reilly TP, DeVona DA et al (2007) Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 34:2365–2373

    CAS  PubMed  Google Scholar 

  36. Nash P, Nayiager S, Genovese MC et al (2013) Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III international, multicenter, parallel-arm, open-label study. Arthritis Care Res 65:718–728

    Article  CAS  Google Scholar 

  37. Kaine J, Gladstein G, Strusberg I et al (2012) Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 71:38–44

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double blind, placebo-controlled withdrawal trial. Lancet 372:383–392

    Article  CAS  PubMed  Google Scholar 

  39. Dueckers G, Guellac N, Arbogast M et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142:176–193

    Article  CAS  PubMed  Google Scholar 

  40. Record JL, Beukelman T, Cron RQ (2011) Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 38:180–181

    Article  PubMed  Google Scholar 

  41. Zulian F, Balzarin M, Falcini F et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62:821–825

    Article  CAS  Google Scholar 

  42. Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficiency of abatocept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792–1802

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. K. Krüger gibt Beratungs- und Vortragstätigkeit für die Firma Bristol Myers &Squibb an. J.-P. Haas hat von der Firma Bristol-Myers Squibb Vortrags- und Beraterhonorare erhalten. M. Gaubitz erhielt Vortragshonorare, Beratungshonorare, Reisekostenunterstützung von Abbott, Abbvie, Amgen, BMS, Chugai, Hexal, Janssen, Merck, MSD, Mundipharma, Pfizer, Roche, Servier, SOBI und UCB. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Akademie für Manuelle Therapie an der WWU Münster, Münster, Deutschland

    M. Gaubitz

  2. Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland

    K. Krüger

  3. Deutsches Zentrum für Kinder- & Jugendrheumatologie, Kinderklinik Garmisch-Partenkirchen, Garmisch-Partenkirchen, Deutschland

    J.-P. Haas

Authors
  1. M. Gaubitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.-P. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Die Kommission Pharmakotherapie der DGRh

Corresponding author

Correspondence to K. Krüger.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaubitz, M., Krüger, K., Haas, JP. et al. Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis. Z. Rheumatol. 73, 942–949 (2014). https://doi.org/10.1007/s00393-014-1373-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1373-4

Search

Navigation